我們諾博萊德公司作為SYnAbs公司的經(jīng)銷商，介紹一下SYnAbs公司：
SYnAbs公司是一家生命科學(xué)研究試劑生產(chǎn)商。
SynAbs公司于2015年9月在PierreGianello教授的實(shí)驗(yàn)性手術(shù)實(shí)驗(yàn)室（CHEX）成立，目的是開發(fā)定制生產(chǎn)單克隆抗體的專業(yè)知識(shí)，這些單克隆抗體主要是老鼠，但也是豚鼠。
SynAbs目前擁有130平方米的生產(chǎn)實(shí)驗(yàn)室。
SynAbs公司選擇開發(fā)自己的Syn2.2骨髓瘤細(xì)胞系來制造豚鼠單克隆抗體；可提供單克隆抗體定制服務(wù)。
SynAbs 目前參與生產(chǎn)用于CROs（單克隆抗體和定制免疫測(cè)定）的大鼠單克隆抗體，并且擁有大量的二級(jí)單克隆抗體（超過一百種二級(jí)抗免疫球蛋白）已獲得上的廣泛認(rèn)可，其創(chuàng)始人（皮埃爾Gianello，Yannick Nizet和Didier Argentin）希望進(jìn)一步增加。
由于其由CSO Yannick Nizet，PhD領(lǐng)導(dǎo)的6位科學(xué)家以及其姊妹公司Rd-Biotech和法國Diaclone提供的廣泛生物技術(shù)支持，SynAbs確實(shí)可以提供一站式服務(wù)組合，覆蓋抗原合成和半抗原載體的化學(xué)反應(yīng)，通過小鼠，大鼠和豚鼠的平行免疫，直到這些小鼠，大鼠和豚鼠單克隆抗體的克級(jí)水平的定制生成和制造。這個(gè)*的三重免疫平臺(tái)使SynAbs能夠提高您尋找*單克隆抗體的可能性，從而大限度地提高我們客戶的成功率！可滿足客戶在開發(fā)，驗(yàn)證和測(cè)試各個(gè)階段的要求。
SYnAbs公司主要產(chǎn)品線：一抗和二抗產(chǎn)品
我們北京諾博萊德科技有限公司作為SYnAbs公司的經(jīng)銷商為客戶提供，正規(guī)進(jìn)口，貨期穩(wěn)定，折扣好的服務(wù)標(biāo)準(zhǔn)。
SYnAbs公司*產(chǎn)品：
產(chǎn)品名稱 | 貨號(hào) | 規(guī)格 |
Mouse IgG3 heavy chain, Purified, Clone: LO-MG3-13, Isotype:IgG1 kappa(ELISA, SAI, IC, Cryosection, DOT-ELISPOT) | LO-MG3-13-P-10 | 10ml |
Negative control, Purified, Clone: IR162, Isotype:IgE kappa | IR162-P-5 | 5ml |
Human leucocytes, Purified, Clone: LO-CD6-a, Isotype:IgG2a kappa(Identification of mature T cells) | LO-CD6-a-P-1 | 1ml |
Dinitrophenyl hapten, FITC, Clone: MADNP-5, Isotype:IgM | MADNP-5-FITC-0.5 | 0.5ml |
Negative control, Purified, Clone: IR162, Isotype:IgE kappa | IR162-P-10 | 10ml |
Human leucocytes, Purified, Clone: LO-CD6-a, Isotype:IgG2a kappa(Identification of mature T cells) | LO-CD6-a-P-5 | 5ml |
Dinitrophenyl hapten, FITC, Clone: MADNP-5, Isotype:IgM | MADNP-5-FITC-1 | 1ml |
Negative control, Purified, Clone: IR595, Isotype:IgG1 kappa | IR595-P-0.1 | 0.1ml |
Human leucocytes, Purified, Clone: LO-CD6-a, Isotype:IgG2a kappa(Identification of mature T cells) | LO-CD6-a-P-10 | 10ml |
Anti afla-toxine, Purified, Clone: LO-Afla | LO-Afla-P-0.1 | 0.1ml |
Mouse IgG3 heavy chain, Biotin, Clone: LO-MG3-13, Isotype:IgG1 kappa(ELISA, SAI, IC, Cryosection, DOT-ELISPOT) | LO-MG3-13-BIOT-0.5 | 0.5ml |
Negative control, Purified, Clone: IR595, Isotype:IgG1 kappa | IR595-P-0.5 | 0.5ml |
Human leucocytes, FITC, Clone: LO-CD6-a, Isotype:IgG2a kappa(Identification of mature T cells) | LO-CD6-a-FITC-0.5 | 0.5ml |
Anti afla-toxine, Purified, Clone: LO-Afla | LO-Afla-P-0.5 | 0.5ml |
Mouse IgG3 heavy chain, Biotin, Clone: LO-MG3-13, Isotype:IgG1 kappa(ELISA, SAI, IC, Cryosection, DOT-ELISPOT) | LO-MG3-13-BIOT-1 | 1ml |
Negative control, Purified, Clone: IR595, Isotype:IgG1 kappa | IR595-P-1 | 1ml |
Human leucocytes, FITC, Clone: LO-CD6-a, Isotype:IgG2a kappa(Identification of mature T cells) | LO-CD6-a-FITC-1 | 1ml |
Anti afla-toxine, Purified, Clone: LO-Afla | LO-Afla-P-1 | 1ml |
Mouse IgG3 heavy chain, FITC, Clone: LO-MG3-13, Isotype:IgG1 kappa(ELISA, SAI, IC, Cryosection, DOT-ELISPOT) | LO-MG3-13-FITC-0.5 | 0.5ml |
Negative control, Purified, Clone: IR595, Isotype:IgG1 kappa | IR595-P-5 | 5ml |
Human leucocytes, Purified, Clone: LO-CD9, Isotype:IgG1 kappa(In vitro elimination of leukemic cells) | LO-CD9-P-0.1 | 0.1ml |
Anti afla-toxine, Purified, Clone: MA-Afla | MA-Afla-P-0.1 | 0.1ml |
Mouse IgG3 heavy chain, FITC, Clone: LO-MG3-13, Isotype:IgG1 kappa(ELISA, SAI, IC, Cryosection, DOT-ELISPOT) | LO-MG3-13-FITC-1 | 1ml |
Negative control, Purified, Clone: IR595, Isotype:IgG1 kappa | IR595-P-10 | 10ml |
Human leucocytes, Purified, Clone: LO-CD9, Isotype:IgG1 kappa(In vitro elimination of leukemic cells) | LO-CD9-P-0.5 | 0.5ml |
Anti afla-toxine, Purified, Clone: MA-Afla | MA-Afla-P-0.5 | 0.5ml |
Rat Kappa light chain, Purified, Clone: MARK-1, Isotype:IgG1 kappa(ELISA, SAI, IC, cryosection) | MARK-1-P-0.1 | 0.1ml |
Negative control, Purified, Clone: IR871, Isotype:IgG1 kappa | IR871-P-0.1 | 0.1ml |
Human leucocytes, Purified, Clone: LO-CD9, Isotype:IgG1 kappa(In vitro elimination of leukemic cells) | LO-CD9-P-1 | 1ml |
Anti afla-toxine, Purified, Clone: MA-Afla | MA-Afla-P-1 | 1ml |
Rat Kappa light chain, Purified, Clone: MARK-1, Isotype:IgG1 kappa(ELISA, SAI, IC, cryosection) | MARK-1-P-0.5 | 0.5ml |
Negative control, Purified, Clone: IR871, Isotype:IgG1 kappa | IR871-P-0.5 | 0.5ml |
Human leucocytes, Purified, Clone: LO-CD9, Isotype:IgG1 kappa(In vitro elimination of leukemic cells) | LO-CD9-P-5 | 5ml |
Anti IgGT Horse, Purified, Clone: LO-HO GT-1 | LO-HoGT-1-P-0.1 | 0.1ml |
Rat Kappa light chain, Purified, Clone: MARK-1, Isotype:IgG1 kappa(ELISA, SAI, IC, cryosection) | MARK-1-P-1 | 1ml |
Negative control, Purified, Clone: IR871, Isotype:IgG1 kappa | IR871-P-1 | 1ml |
Human leucocytes, Purified, Clone: LO-CD9, Isotype:IgG1 kappa(In vitro elimination of leukemic cells) | LO-CD9-P-10 | 10ml |
Anti IgGT Horse, Purified, Clone: LO-HO GT-1 | LO-HoGT-1-P-0.5 | 0.5ml |
Rat Kappa light chain, Purified, Clone: MARK-1, Isotype:IgG1 kappa(ELISA, SAI, IC, cryosection) | MARK-1-P-5 | 5ml |
Negative control, Purified, Clone: IR871, Isotype:IgG1 kappa | IR871-P-5 | 5ml |
Human leucocytes, Purified, Clone: LO-CDw41, Isotype:IgG2a kappa(Identification of acute myeloblastic leukemia involving the megakaryocytic lineage) | LO-CDw41-P-0.1 | 0.1ml |
Anti IgGT Horse, Purified, Clone: LO-HO GT-1 | LO-HoGT-1-P-1 | 1ml |
Rat Kappa light chain, Purified, Clone: MARK-1, Isotype:IgG1 kappa(ELISA, SAI, IC, cryosection) | MARK-1-P-10 | 10ml |
Negative control, Purified, Clone: IR871, Isotype:IgG1 kappa | IR871-P-10 | 10ml |
Human leucocytes, Purified, Clone: LO-CDw41, Isotype:IgG2a kappa(Identification of acute myeloblastic leukemia involving the megakaryocytic lineage) | LO-CDw41-P-0.5 | 0.5ml |
Anti IgGT Horse, Purified, Clone: LO-HoGT- 2 | LO-HoGT- 2-P-0.1 | 0.1ml |
Negative control, Purified, Clone: IR27, Isotype:IgG1 kappa | IR27-P-0.1 | 0.1ml |
Human leucocytes, Purified, Clone: LO-CDw41, Isotype:IgG2a kappa(Identification of acute myeloblastic leukemia involving the megakaryocytic lineage) | LO-CDw41-P-1 | 1ml |
Anti IgGT Horse, Purified, Clone: LO-HoGT- 2 | LO-HoGT- 2-P-0.5 | 0.5ml |
Negative control, Purified, Clone: IR27, Isotype:IgG1 kappa | IR27-P-0.5 | 0.5ml |
會(huì)員_a.png)